Table 3.
Lipid profile and safety parameters before and after the treatment.
| Baseline (n = 52) | EOT (n = 50) | Treatment difference | P | ||
|---|---|---|---|---|---|
| LDL (mg/dl) | 156.6 ± 35.4 | 133.9 ± 30.3 | −24.5 ± 22.8 | −15.6% | <0.001 |
| TC (mg/dl) | 241.0 ± 40.4 | 216.4 ± 36.2 | −24.7 ± 23.9 | −10.2% | <0.001 |
| HDL (mg/dl) | 56.0 ± 15.3 | 57.2 ± 14.1 | 1.8 ± 6.7 | 3.2% | 0.057 |
| Triglycerides (mg/dl) | 107.5 (82.3–171.3) | 100.5 (78.0–148.3) | −13.5 (−40.5 – 18.25) | −12.6% | 0.032 |
| nonHDL cholesterol (mg/dl) | 185.0 ± 39.0 | 159.1 ± 35.2 | −26.5 ± 24.3 | −14.3% | <0.001 |
| TC/HDL | 4.6 ± 1.3 | 4.0 ± 1.0 | −0.68 ± 0.72 | −14.8% | <0.001 |
| nonHDL/HDL | 3.58 ± 1.32 | 2.96 ± 0.99 | −0.68 ± 0.72 | −19.0% | <0.001 |
| LDL/HDL | 2.9 ± 0.9 | 2.5 ± 0.7 | −0.5 ± 0.5 | −17.2% | <0.001 |
| AIP | 0.01 ± 0.36 | −0.06 ± 0.28 | −0.07 ± 0.21 | −7% | 0.025 |
| ApoB (mg/dl) | 112.2 ± 21.1 | 94.3 ± 19.5 | −18.5 ± 13.1 | −16.5% | <0.001 |
| ApoA1 (mg/dl) | 142.7 ± 17.9 | 144.6 ± 17.4 | 3.0 ± 7.9 | 2.1% | 0.01 |
| ApoB/ApoA1 | 0.80 ± 0.19 | 0.66 ± 0.17 | −0.15 ± 0.09 | −18.8% | <0.001 |
| AST (U/L) | 22.4 ± 4.9 | 23.3 ± 6.2 | 0.9 ± 3.9 | 4% | 0.103 |
| ALT (U/L) | 19.6 ± 7.3 | 20.6 ± 7.7 | 1.0 ± 4.5 | 5.1% | 0.120 |
| CK (U/L) | 144.5 ± 84.5 | 139.2 ± 71.3 | −5.4 ± 50.7 | −3.7% | 0.458 |
| Creatinine (mg/dl) | 0.82 ± 0.13 | 0.83 ± 0.14 | 0.01 ± 0.06 | 1.2% | 0.181 |
The variables normally distributed are presented as mean ± SD, otherwise as median (IQR). EOT, end of treatment; AIP, atherogenic index of plasma [log(triglycerides/HDL)].